Global Undervalued Small Caps With Insider Action To Enhance Your Portfolio
As global markets navigate mixed signals, with major U.S. indices like the S&P 600 for small-cap stocks experiencing some declines amid broader economic uncertainties, investors are keenly observing potential opportunities in undervalued segments. In this climate, small-cap stocks with notable insider activity can offer intriguing prospects for portfolio diversification and growth potential.
Top 10 Undervalued Small Caps With Insider Buying Globally
| Name | PE | PS | Discount to Fair Value | Value Rating |
|---|---|---|---|---|
| Natural Food International Holding | 8.8x | 1.0x | 49.04% | ★★★★★☆ |
| Eurocell | 12.9x | 0.3x | 44.94% | ★★★★★☆ |
| Bilia | 15.9x | 0.3x | 31.18% | ★★★★☆☆ |
| Nexus Industrial REIT | 10.4x | 3.1x | 6.88% | ★★★★☆☆ |
| Linc | 12.9x | 13.4x | 30.19% | ★★★★☆☆ |
| Sagicor Financial | 7.2x | 0.5x | -86.69% | ★★★★☆☆ |
| Pizza Pizza Royalty | 12.8x | 9.8x | 35.74% | ★★★☆☆☆ |
| Chinasoft International | 23.4x | 0.5x | -88.12% | ★★★☆☆☆ |
| ATS | 52.8x | 0.9x | 35.21% | ★★★☆☆☆ |
| Hong Fok | 23.2x | 6.7x | 30.29% | ★★★☆☆☆ |
Below we spotlight a couple of our favorites from our exclusive screener.
GenusPlus Group (ASX:GNP)
Simply Wall St Value Rating: ★★★☆☆☆
Overview: GenusPlus Group operates in the services, infrastructure, and energy and engineering sectors, with a focus on providing integrated solutions across these industries; the company has a market cap of A$0.25 billion.
Operations: GenusPlus Group's primary revenue streams are derived from Infrastructure and Energy and Engineering, contributing significantly to its financial performance. The company has experienced fluctuations in its gross profit margin, which reached 77.31% as of December 2024 but adjusted to 73.79% by March 2026. Operating expenses have been a substantial part of the cost structure, with General & Administrative Expenses being a significant component.
PE: 33.8x
GenusPlus Group, a smaller company in the market, has shown promising growth with sales jumping to A$1.28 billion for the year ending June 2026 from A$751 million previously. Net income rose to A$49 million, reflecting strong operational performance. Insider confidence is evident with recent share purchases, signaling belief in future prospects. Despite relying solely on external borrowing for funding, earnings are projected to grow annually by 22.99%. Dividends increased significantly by 55% from fiscal 2025, highlighting financial health and potential value for investors seeking growth opportunities in smaller companies.
- Unlock comprehensive insights into our analysis of GenusPlus Group stock in this valuation report.
Review our historical performance report to gain insights into GenusPlus Group's's past performance.
PZ Cussons (LSE:PZC)
Simply Wall St Value Rating: ★★★☆☆☆
Overview: PZ Cussons is a consumer products company operating in personal care, home care, and beauty sectors across Africa, Asia Pacific, Europe & The Americas with a market capitalization of approximately £1.09 billion.
Operations: The company generates revenue from multiple geographic regions, with Europe & The Americas and Asia Pacific being significant contributors. The cost of goods sold (COGS) has been a substantial component of expenses, influencing the gross profit margin, which was 40.52% as of September 2026. Operating expenses include notable allocations to sales and marketing, as well as general and administrative costs.
PE: 21.9x
PZ Cussons, a company with a market cap under GBP 1 billion, has shown signs of being undervalued. Recent financial results highlight a turnaround with sales reaching GBP 541 million and net income at GBP 19.8 million for the year ending May 2026, shifting from last year's loss. Insider confidence is evident as they have been purchasing shares in recent months, suggesting belief in future growth prospects. However, reliance on external borrowing poses some risk despite earnings expected to grow by over 17% annually.
- Click to explore a detailed breakdown of our findings in PZ Cussons' valuation report.
Gain insights into PZ Cussons' historical performance by reviewing our past performance report.
AK Medical Holdings (SEHK:1789)
Simply Wall St Value Rating: ★★★★★★
Overview: AK Medical Holdings specializes in the development, production, and distribution of orthopedic implants, with operations primarily in China and the United Kingdom.
Operations: The company generates revenue primarily from orthopedic implants in China, contributing significantly to its total income, with additional sales from the United Kingdom. The cost of goods sold (COGS) and operating expenses are substantial components of its expenditure. Over recent periods, the gross profit margin has shown varied percentages, with a notable 62.75% in June 2026.
PE: 12.6x
AK Medical Holdings, a smaller company in the medical device sector, recently reported half-year sales of CNY 764.73 million, up from CNY 694.23 million last year. Net income also rose to CNY 196.72 million from CNY 160.61 million, showcasing potential growth despite higher risk funding through external borrowing only. Insider confidence is evident as VP & Executive Director Xiaohong Zhao purchased 200,000 shares for approximately ¥1.02 million in August 2026, indicating belief in future prospects with forecasted earnings growth of over 11% annually and expected overseas revenue surge by around 40%.
- Click here to discover the nuances of AK Medical Holdings with our detailed analytical valuation report.
Evaluate AK Medical Holdings' historical performance by accessing our past performance report.
Where To Now?
- Gain an insight into the universe of 105 Undervalued Global Small Caps With Insider Buying by clicking here.
- Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
- Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.
Ready To Venture Into Other Investment Styles?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com